This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Innovations of Dilip Jadhav in Pharmaceutical Chemistry
Introduction
Dilip Jadhav is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific receptors associated with various diseases. His work is characterized by a focus on innovative solutions for complex medical conditions.
Latest Patents
Dilip Jadhav holds a patent for a compound titled "1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists." This invention provides a compound represented by a specific formula, which exhibits EP4 receptor antagonistic action. It is useful as an agent for the prophylaxis or treatment of EP4 receptor-associated diseases, including rheumatoid arthritis, aortic aneurysms, endometriosis, ankylosing spondylitis, and inflammatory breast cancer. He has 1 patent to his name.
Career Highlights
Dilip Jadhav is currently associated with Takeda Pharmaceutical Company Limited, where he continues to advance his research and development efforts. His work at Takeda emphasizes the importance of innovative drug development aimed at improving patient outcomes.
Collaborations
Dilip collaborates with esteemed colleagues, including Anil Panmand and Anil M Deshpande. These partnerships enhance the research environment and foster the exchange of ideas that lead to groundbreaking innovations.
Conclusion
Dilip Jadhav's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in addressing complex health challenges. His patent work and collaborations reflect a commitment to advancing medical science for the benefit of patients worldwide.